-

12:39:28 PM

BVAXF Stock News

BVAXF - BioVaxys Technology Corp

03/16/23 8:00 AM

OTC : BVAXF

acquisitionclinical trial

BIOVAXYS ACQUIRES CLINICAL STUDY MANAGEMENT COMPANY AND COMPLETES PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") today announced that it has acquired TAETSoftware Corp ("TAETCo"), a Vancouver -based clinical studies management company engaged in the development and

RHEA-AI

neutral

12/19/22 7:00 AM

OTC : BVAXF

BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps

VANCOUVER, British Colombia and BARCELONA, Spain , Dec. 19, 2022 - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") and Procare Health Iberia, of Barcelona, Spain ("Procare Health") announced today that they have finalized and executed the

RHEA-AI

positive

12/05/22 8:00 AM

OTC : BVAXF

conferences

BioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Co-Founder, President & Chief Operating Officer Kenneth Kovan will be presenting at the MedInvest Oncology Investor Conference held in

RHEA-AI

very positive

12/01/22 8:00 AM

OTC : BVAXF

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.The

RHEA-AI

very positive

10/06/22 8:00 AM

OTC : BVAXF

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or

RHEA-AI

positive

09/28/22 8:00 AM

OTC : BVAXF

BioVaxys Further Expands Vaccines Intellectual Property Portfolio

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the patent coverage for its viral vaccine

RHEA-AI

neutral

08/26/22 4:13 AM

OTC : BVAXF

BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of its previously announced non-brokered private placement (the "Private Placement").

RHEA-AI

neutral

06/15/22 8:00 AM

OTC : BVAXF, LMNGF

clinical trial

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer

RHEA-AI

very positive

06/08/22 8:00 AM

OTC : BVAXF, LMNGF

clinical trial

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France -based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next

RHEA-AI

neutral

06/03/22 8:00 AM

OTC : BVAXF, LMNGF

BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that The Ohio State University (" Ohio State"), its research collaborator that is

RHEA-AI

neutral